Search

Displaying results 9361 - 9370 of 10000 in total
  1. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

  2. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant has a monoisotopic molecular weight of 478.13 Da. … Eliapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.

  3. Drug

    NV-07a

    go.drugbank.com/drugs/DB05845
    Experimental

    NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.

  4. Drug

    ENMD-1198

    go.drugbank.com/drugs/DB05959
    Experimental

  5. Drug

    Trodusquemine

    go.drugbank.com/drugs/DB06333
    Investigational

    Trodusquemine, a spermine metabolite of cholesterol, is a naturally occurring aminosterol that inhibits protein tyrosine phosphatase 1B.

  6. Drug

    G4460

    go.drugbank.com/drugs/DB06359
    Investigational

  7. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  8. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    It is considered to be a systemic anti-inflammatory and neuroprotective agent. … VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.

  9. Drug

    Dacetuzumab

    go.drugbank.com/drugs/DB12589
    Investigational

    It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.

  10. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action".